IMPACT Therapeutics today announced clinical data for two ongoing trials to be presented at the upcoming ASCO2022 to be held Jun 3 to 7, 2022 (Chicago, US). A poster will present the preliminary results of the phase 1b/2 study investigating the PARP inhibitor Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors and extensive stage small cell lung cancer. An abstract publication will present preliminary data from the dose escalation part in the first-in-human study for the Wee1 inhibitor IMP7068.

Highlights of the poster/abstract (refer to ASCO2022 for more details)

About IMPACT Therapeutics

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received US IND Clearance from FDA and China IND application from NMPA and the first patient has been dosed in the US. Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA.